Immunoassay Market 1 14

Vaccines & Drugs market growth at a CAGR of ~ 16.7% from 2021 to 2027


New York, United States: The Report on Vaccines & Drugs Market by Decisive Markets Insights was released in the middle of Covid -19 after a thorough analysis of the top players and primary interviews with key industry figures. A market study from Vaccines & Drugs Market examines the market size, segmentation, future trends, growth rate, drivers and challenges, as well as the sales channels and distributors. The global Vaccines & Drugs market gathered revenue around USD 2,271 Million in 2021 and market is set to grow USD 1,502 Million by the end of 2027 and is estimated to expand at a modest CAGR of 16.7% during the prediction period 2021 to 2027

Overview of Vaccines & Drugs Market Study

Vaccines & Drugs market study conducted by Nova One Advisor is intended at helping stakeholders get a comprehensive overview of potential challenges and undiscovered opportunities. The report offers exclusive insights to help companies and their customers to make informed decision to sustain growth through the assessment period.

Get your Customized Research Report@

Growth Factors:

The growth of the COVID vaccines market is attributed majorly to the rising number of people infected with COVID-19 and increasing funding for vaccine development. The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, and the emergence of alternative therapies such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1. Moreover, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies are fueling the market growth.

Funding from global governments and foundations is promoting the growth of the market

Incentives are needed to engage manufacturers for the large-scale capacity to guarantee sufficient production of SARS-CoV-2 vaccines. In line with this, various global organizations have come forward to expedite the process, such as Gavi, CEPI, and WHO. However, considering the pandemic scenario of COVID-19, much stronger initiatives are required.

In April 2020, the Bill and Melinda Gates Foundation announced plans to help fund factories for seven promising vaccines, even before seeing conclusive data. The foundation aims to help scale up manufacturing during testing, rather than after the vaccines have passed the trials.

Besides the most promising Moderna program, several other big pharma companies are involved in COVID-19 vaccine work. Johnson & Johnson has pledged a manufacturing scale-up to 1 billion doses for its federally partnered program. Meanwhile, Sanofi has two partnerships underway—one with the federal government and another with Translate Bio.

Vaccine manufacturing ramp-up to drive the growth further

While global drug makers are pouring massive resources into developing targeted therapies and vaccines, contract development and manufacturing organizations (CDMOs) are finding ways to ramp up the production of vaccines. In line with this, a new CDMO from Belgium’s Univercells is offering its expertise to help drug makers scale up their manufacturing.

Pfizer and BioNTech have initiated plans for clinical trials and producing millions of doses, if the trials succeed. The companies expect to have millions of doses of a COVID-19 vaccine ready to go by year-end if the companies begin human testing as planned by late April. Pfizer and BioNTech are hoping to advance multiple mRNA vaccine candidates.

Currently, around 155 molecules are under clinical investigation, and about 45 molecules are under preclinical development to be targeted against COVID-19. In this list, four promising drugs have been repurposed for use against COVID-19.

  • Remdesivir
  • Chloroquine and hydroxychloroquine
  • Lopinavir and ritonavir (and that same combination plus interferon-beta)
  • An immune system messenger that can help stop the multiplication of viruses.

Researchers and physicians in several countries are focusing on various other existing drugs to examine their potential to treat COVID-19. Chinese authorities, which have been dealing with the virus longer, are recommending Arbidol (umifenovir), which has not been approved in Western countries, as well as old antivirals ribavirin and interferon-alpha. Similarly, Avigan (favipiravir) by Fujifilm has shown promise in the treatment of COVID-19.

As the maximum number of molecules are repurposed drugs that are already approved for other infections and inflammatory diseases, higher stages of development (namely phase 2 trials) hold the largest share. China, along with other Asian countries, holds the largest share of the number of clinical trials being conducted, followed by Europe and the US. Small molecules accounted for the largest share, followed by monoclonal antibodies and plasma and cell therapy.

AI-powered technologies are making the drug discovery process more efficient and substantially improve success rates at the early stages of drug development. Artificial intelligence algorithms ingest and analyze a vast amount of information and can identify potential drug candidates in lesser time. Such factors will expedite the drug development process.

Buy Complete Assessment of Vaccines & Drugs market Now@

COVID-19 Impact on Vaccines & Drugs Sales

Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the Vaccines & Drugs market.

Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.

Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.

Against this backdrop, Nova one advisor’s study predicts gradual recovery for the Vaccines & Drugs market 2021 onwards. This trend will however continue through the course of the report’s assessment period

Key Players:

This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the Vaccines & Drugs market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the Vaccines & Drugs market include: Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) among others.

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:


The current pipeline of vaccines by phase by companies

Competitive landscape (top players in vaccines)

  • Viewpoint on COVID-19 pipeline
  • Impact of COVID-19 on other vaccines in the portfolio/other under development vaccines

Macroeconomic indicators

  • Drivers
  • Restraints
  • New opportunities

Post COVID-19 vaccine approval scenario

  • Challenges in vaccines approval/production/supply
  • Strategies to overcome challenges
    • Historic examples (SARS, MERS, Ebola, H1N1)
    • New strategies

Strategies to ramp up production at a pandemic level

  • Historic examples
  • New strategies

Covid-19 vaccine market estimation

  • Epidemiology model (assumption basis)
  • Pricing strategies (compared to current flu vaccines)
  • Covid-19 vaccine market (optimistic, pessimistic & realistic)

Therapeutic drugs

The current pipeline of drugs by phase by companies

Competitive landscape (top players in COVID-19 therapeutic drugs)

  • A view point on the COVID-19 pipeline
  • Impact of COVID-19 on other products in the portfolio/other under development products

Macroeconomic indicators

  • Drivers
  • Restraints
  • New opportunities

Post COVID-19 approval scenario

  • Challenges in production/manufacturing
  • Strategies to overcome challenges
    • Historic examples (SARS, MERS, Ebola, H1N1)
    • New strategies

Strategies to ramp up production at a pandemic level

  • Historic examples
  • New strategies

Covid-19 vaccine market estimation

  • Epidemiology model (assumption basis)
  • Pricing strategies
  • Repurpose drugs
  • New molecules
  • Covid-19 therapy market (optimistic, pessimistic & realistic)

Why Buy this Report?

The purpose of Nova one advisor’s Vaccines & Drugs market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Download This Full Research Report, Click Here@

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333



James Root

James Root have over 6+ years of experience working in business development, and customer retention. I’ve gained my experience through serving higher education, healthcare, automotive, aerospace, manufacturing, local government and hospitality businesses with technical solutions.

View all posts by James Root →

Leave a Reply

Your email address will not be published.